BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 30319123)

  • 1. [Castration resistance mechanisms in prostate cancer.].
    Martínez-Breijo S; Chantada-Abal V; Aller-Rodríguez M; Bohórquez-Cruz M; Sacristán-Lista F; Ponce-Díaz J; Vázquez-Martul D; Lamas-Díaz L
    Arch Esp Urol; 2018 Sep; 71(8):628-638. PubMed ID: 30319123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
    Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
    Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
    Fujimoto N
    J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
    Chandrasekar T; Yang JC; Gao AC; Evans CP
    Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.
    Crona DJ; Whang YE
    Cancers (Basel); 2017 Jun; 9(6):. PubMed ID: 28604629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
    Coutinho I; Day TK; Tilley WD; Selth LA
    Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
    Cai Z; Chen W; Zhang J; Li H
    Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.
    Kahn B; Collazo J; Kyprianou N
    Int J Biol Sci; 2014; 10(6):588-95. PubMed ID: 24948871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen Signaling in Prostate Cancer.
    Dai C; Heemers H; Sharifi N
    Cold Spring Harb Perspect Med; 2017 Sep; 7(9):. PubMed ID: 28389515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor.
    Tilki D; Schaeffer EM; Evans CP
    Eur Urol Focus; 2016 Dec; 2(5):499-505. PubMed ID: 28723515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
    Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
    Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
    Wadosky KM; Koochekpour S
    Oncotarget; 2016 Sep; 7(39):64447-64470. PubMed ID: 27487144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials.
    Ebrahimi S; Hashemy SI; Sahebkar A; Aghaee Bakhtiari SH
    Curr Mol Pharmacol; 2021 Oct; 14(4):559-569. PubMed ID: 33357209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interplay between orphan nuclear receptors and androgen receptor-dependent or-independent growth signalings in prostate cancer.
    Wang Y; Gao W; Li Y; Chow ST; Xie W; Zhang X; Zhou J; Chan FL
    Mol Aspects Med; 2021 Apr; 78():100921. PubMed ID: 33121737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The changing landscape of advanced and castration resistant prostate cancer: latest science and revised definitions.
    Tilki D; Evans CP
    Can J Urol; 2014 Apr; 21(2 Supp 1):7-13. PubMed ID: 24775718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ; Milowsky MI; Whang YE
    Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.